‘Decarbonising industry’: Prashant Ruia on Essar’s energy transition
Essar acquired the Stanlow refinery from Shell in 2011, investing £769 million into the site, which produces 16 per cent of the nations’s fuel.
Ruia emphasised the UK’s global leadership in clean energy, saying that no other country today has a policy as clear and fast-moving. (Photo: X/@prashantruia)
By EasternEyeOct 28, 2024
PRASHANT Ruia, CEO of the Essar Group, has outlined ambitious plans for Essar’s Stanlow refinery in Cheshire, aiming to make it the country's first hydrogen-powered facility.
Speaking to The Times, Ruia emphasised that this project marks a major shift in the UK’s green energy strategy, with Essar committing to decarbonising industries across the North West.
“We are going to decarbonise the industry around the whole of the North West,” he said.
Essar acquired the Stanlow refinery from Shell in 2011, investing £769 million into the site, which produces 16 per cent of the nations’s fuel.
While parts of the 100-year-old refinery are heavily corroded and disused, a new hydrogen-powered section is under construction. “It’s the first refinery to move away from CO2-emitting gas in the UK,” Ruia told the newspaper.
The vision includes implementing carbon-capture technology in various parts of the refinery, with plans to store the carbon emissions in disused gas fields beneath Liverpool Bay.
However, Ruia explained that Essar’s first focus is building a plant to produce hydrogen, adding, “This will have 350 megawatts of generating capacity.” He said a second hydrogen plant could follow, noting that hydrogen not used by the refinery would support neighbouring factories in reducing emissions.
Ruia emphasised the UK’s global leadership in clean energy initiatives, stating, “These are the premier projects of this size in the world. There is no other country today which has this policy so clear and so fast-moving ahead.” He also highlighted the £16.7 billion in government funding for similar projects in Humberside, and said, “I don’t think people give enough credit for the strides Britain has taken.”
Ruia reflected on his early days in business, recounting a lesson learned on his first major project at 17: building a rail bridge in Mumbai’s suburbs. “They wouldn’t wait for you to grow up before they gave you responsibility,” he said. Though the project incurred a £192,308 loss, his father said, “That’s the best money I ever lost in my life, because of what you learnt.”
Essar Energy, which includes Stanlow, turned a profit of £287 million last year on £9.4 billion in sales. Reflecting on Essar’s divestments, including the sale of its mobile phone stake for £3.85 billion, Ruia said, “We de-levered our balance sheet by more than £15.4 billion,” adding, “It gave us an opportunity to start investing much more heavily in this energy transition now.”
The Ruias, who initially rose to wealth following India’s market liberalisation in the 1990s, remain committed to evolving their legacy, with Ruia noting his family’s support of the transition. “They may have taken a little bit more time to get it, but now they get it 200 per cent. This is real, not an idea any more. It’s happening.”
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.